GLP-1–Based Therapies: The Dilemma of Uncertainty
- 31 July 2011
- journal article
- editorial
- Published by Elsevier BV in Gastroenterology
- Vol. 141 (1), 20-23
- https://doi.org/10.1053/j.gastro.2011.05.019
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- A cohort study of acute pancreatitis in relation to exenatide useDiabetes, Obesity and Metabolism, 2011
- Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist UseAnnals of Pharmacotherapy, 2010
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitisInternational Journal of Clinical Practice, 2010
- Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1Endocrinology, 2010
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreasDiabetologia, 2009
- Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in MiceDiabetes, 2009
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurrent Medical Research and Opinion, 2009
- Exenatide and Rare Adverse EventsNew England Journal of Medicine, 2008
- Exenatide (Exendin-4)–Induced PancreatitisDiabetes Care, 2006